News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
268,812 Results
Type
Article (13957)
Company Profile (103)
Press Release (254751)
Multimedia
Podcasts (53)
Webinars (13)
Section
Business (88183)
Career Advice (473)
Deals (15365)
Drug Delivery (67)
Drug Development (36643)
Employer Resources (49)
FDA (6320)
Job Trends (6213)
News (150464)
Policy (14080)
Tag
Academia (442)
Accelerated approval (4)
Adcomms (6)
Allergies (44)
Alliances (23324)
ALS (44)
Alzheimer's disease (434)
Antibody-drug conjugate (ADC) (56)
Approvals (6383)
Artificial intelligence (137)
Autoimmune disease (10)
Automation (6)
Bankruptcy (150)
Best Places to Work (4371)
BIOSECURE Act (9)
Biosimilars (71)
Biotechnology (41)
Bladder cancer (24)
Brain cancer (20)
Breast cancer (110)
Cancer (854)
Cardiovascular disease (90)
Career advice (414)
Career pathing (12)
CAR-T (31)
CDC (3)
Cell therapy (106)
Cervical cancer (6)
Clinical research (31304)
Collaboration (457)
Compensation (209)
Complete response letters (19)
COVID-19 (766)
CRISPR (28)
C-suite (200)
Cystic fibrosis (46)
Data (971)
Denatured (16)
Depression (18)
Diabetes (97)
Diagnostics (1339)
Digital health (2)
Diversity (2)
Diversity, equity & inclusion (14)
Drug discovery (72)
Drug pricing (82)
Drug shortages (12)
Duchenne muscular dystrophy (56)
Earnings (32669)
Editorial (14)
Employer branding (4)
Employer resources (44)
Events (38060)
Executive appointments (472)
FDA (6969)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (289)
Gene editing (46)
Generative AI (9)
Gene therapy (119)
GLP-1 (383)
Government (1335)
Grass and pollen (4)
Guidances (97)
Healthcare (3574)
HIV (7)
Huntington's disease (5)
IgA nephropathy (19)
Immunology and inflammation (50)
Immuno-oncology (2)
Indications (21)
Infectious disease (808)
Inflammatory bowel disease (60)
Inflation Reduction Act (7)
Influenza (15)
Intellectual property (67)
Interviews (61)
IPO (5904)
IRA (32)
Job creations (2055)
Job search strategy (378)
Kidney cancer (7)
Labor market (19)
Layoffs (191)
Leadership (4)
Legal (3443)
Liver cancer (20)
Longevity (6)
Lung cancer (117)
Lymphoma (73)
Machine learning (4)
Management (16)
Manufacturing (226)
MASH (45)
Medical device (1298)
Medtech (1300)
Mergers & acquisitions (9740)
Metabolic disorders (317)
Multiple sclerosis (29)
NASH (14)
Neurodegenerative disease (35)
Neuropsychiatric disorders (12)
Neuroscience (670)
NextGen: Class of 2025 (1588)
Non-profit (606)
Now hiring (12)
Obesity (175)
Opinion (130)
Ovarian cancer (27)
Pain (72)
Pancreatic cancer (29)
Parkinson's disease (52)
Partnered (7)
Patents (156)
Patient recruitment (50)
Peanut (12)
People (29247)
Pharmaceutical (64)
Pharmacy benefit managers (14)
Phase I (8145)
Phase II (13234)
Phase III (11898)
Pipeline (709)
Policy (99)
Postmarket research (1401)
Preclinical (3273)
Press Release (25)
Prostate cancer (64)
Psychedelics (10)
Radiopharmaceuticals (125)
Rare diseases (215)
Real estate (2643)
Recruiting (17)
Regulatory (10339)
Reports (14)
Research institute (568)
Resumes & cover letters (56)
Rett syndrome (1)
RNA editing (5)
RSV (10)
Schizophrenia (45)
Series A (54)
Series B (23)
Service/supplier (3)
Sickle cell disease (36)
Special edition (6)
Spinal muscular atrophy (77)
Sponsored (7)
Startups (1643)
State (2)
Stomach cancer (3)
Supply chain (36)
Tariffs (47)
The Weekly (35)
Vaccines (183)
Venture capital (20)
Weight loss (104)
Women's health (10)
Worklife (4)
Date
Today (19)
Last 7 days (188)
Last 30 days (642)
Last 365 days (11054)
2025 (6533)
2024 (12515)
2023 (14265)
2022 (19566)
2021 (20069)
2020 (19038)
2019 (14892)
2018 (11723)
2017 (13896)
2016 (13132)
2015 (15477)
2014 (12425)
2013 (10596)
2012 (11404)
2011 (11931)
2010 (10896)
Location
Africa (316)
Alabama (16)
Alaska (1)
Arizona (61)
Arkansas (3)
Asia (20403)
Australia (2639)
California (2233)
Canada (1120)
China (349)
Colorado (88)
Connecticut (91)
Delaware (80)
Europe (39984)
Florida (435)
Georgia (48)
Hawaii (1)
Idaho (9)
Illinois (255)
India (18)
Indiana (168)
Iowa (1)
Japan (146)
Kansas (64)
Kentucky (17)
Louisiana (2)
Maine (2)
Maryland (321)
Massachusetts (1921)
Michigan (35)
Minnesota (119)
Mississippi (1)
Missouri (24)
Montana (8)
Nebraska (6)
Nevada (13)
New Hampshire (6)
New Jersey (997)
New Mexico (7)
New York (658)
North Carolina (469)
North Dakota (2)
Northern California (935)
Ohio (57)
Oklahoma (4)
Oregon (16)
Pennsylvania (544)
Puerto Rico (9)
Rhode Island (11)
South America (504)
South Carolina (5)
Southern California (942)
Tennessee (43)
Texas (310)
United States (9232)
Utah (45)
Virginia (111)
Washington D.C. (38)
Washington State (150)
West Virginia (1)
Wisconsin (23)
268,812 Results for "portola pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis
July 15, 2025
·
5 min read
Press Releases
Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025
March 24, 2025
·
6 min read
Press Releases
Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results
March 26, 2025
·
15 min read
Drug Development
Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update
October 17, 2024
·
5 min read
Regulatory
Kezar’s Lupus Trial Paused After Four Patient Deaths
The clinical hold doesn’t cover its drug’s Investigational New Drug application for autoimmune hepatitis, for which the Phase IIa PORTOLA trial is ongoing.
October 7, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Acumen Pharmaceuticals and JCR Pharmaceuticals Enter Strategic Collaboration, Option and License Agreement to Develop Enhanced Brain Delivery™ Therapy for Alzheimer’s Disease
July 16, 2025
·
10 min read
Press Releases
Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results
July 31, 2025
·
22 min read
Press Releases
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics
August 1, 2025
·
9 min read
Press Releases
Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited
July 30, 2025
·
7 min read
Press Releases
Quoin Pharmaceuticals Provides Product Portfolio Update
July 30, 2025
·
7 min read
1 of 26,882
Next
